{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:56:58Z","timestamp":1781233018818,"version":"3.54.1"},"reference-count":18,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: The management of moderate-to-severe psoriasis in patients with a recent history of internal malignancy is a clinical challenge, as systemic immunosuppressive therapies are often avoided because of concerns about cancer recurrence. While Psoralen and Ultraviolet A (PUVA) photochemotherapy remains a valuable non-immunosuppressive alternative, regional variations in therapeutic response are not well-characterized in this population. This study aimed to evaluate total and segmental Psoriasis Area and Severity Index (PASI) responses to PUVA in patients with chronic plaque psoriasis and recent internal organ malignancy. Methods: This prospective, single-center, real-world cohort study enrolled 20 adults with moderate-to-severe chronic plaque psoriasis and a recent (&lt;5 years) diagnosis of internal organ malignancy in complete remission. Participants received oral PUVA three times weekly for up to 30 sessions. Primary and secondary outcomes included changes in total PASI, segmental PASI (head\/neck, trunk, upper limbs, and lower limbs), and Dermatology Life Quality Index (DLQI) at baseline, completion of therapy, and 6 months post-treatment. Results: PUVA led to a significant reduction in mean total PASI from 18.6 \u00b1 3.2 at baseline to 5.7 \u00b1 6.0 at treatment completion (69% reduction; p &lt; 0.001). However, regional responses differed significantly: the head and neck improved the most (80.4%), followed by the trunk (72.2%) and upper limbs (72.3%), while the lower limbs showed the weakest response (59.5%; p &lt; 0.001). At baseline, trunk contributed the most to total PASI (38%), while post-treatment, lower-limb lesions accounted for approximately 47% of the remaining total disease burden, showing the highest contribution to total PASI of all body regions. At 6 months, the lower limbs remained the most affected area, with significantly lower improvement (52.9%) compared to other regions. Mean DLQI also improved significantly from 17.2 \u00b1 2.8 to 5.6 \u00b1 2.6 (p &lt; 0.001). Conclusions: PUVA is an effective and safe treatment for patients with psoriasis and a recent history of malignancy. Nevertheless, lower-limb psoriasis is relatively recalcitrant and contributes disproportionately to residual disease burden and relapse. These findings support the use of regional PASI assessment to guide individualized management and clinical expectations in this complex patient group.<\/jats:p>","DOI":"10.3390\/jcm15124525","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T01:52:08Z","timestamp":1781229128000},"page":"4525","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Segmental PASI Evaluation Reveals Reduced PUVA Responsiveness of Lower-Limb Psoriasis in Patients with Internal Organ Malignancy"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7672-0395","authenticated-orcid":false,"given":"Miguel","family":"Alpalh\u00e3o","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"},{"name":"Dermatology Research Unit, Gulbenkian Institute of Molecular Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"},{"name":"Cl\u00ednica Cintram\u00e9dica Portela de Sintra, 2710-437 Sintra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-7193","authenticated-orcid":false,"given":"Joana","family":"Antunes","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"},{"name":"Dermatology Research Unit, Gulbenkian Institute of Molecular Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"},{"name":"Dermatology Department, Unidade Local de Sa\u00fade Santa Maria, 1649-035 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8044-8926","authenticated-orcid":false,"given":"Jo\u00e3o Augusto","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"},{"name":"Dermatology Research Unit, Gulbenkian Institute of Molecular Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9473-8553","authenticated-orcid":false,"given":"Ren\u00e9","family":"Santus","sequence":"additional","affiliation":[{"name":"D\u00e9partement RDDM, Mus\u00e9um National d\u2019Histoire Naturelle, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Filipe","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"},{"name":"Dermatology Research Unit, Gulbenkian Institute of Molecular Medicine, University of Lisbon, 1649-004 Lisbon, Portugal"},{"name":"Dermatology Department, Unidade Local de Sa\u00fade Santa Maria, 1649-035 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"ref_1","first-page":"270","article-title":"S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm\u2014Part 2: Specific clinical and comorbid situations","volume":"24","author":"Nast","year":"2026","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sebbag, E., Lauper, K., Molina-Collada, J., Aletaha, D., Askling, J., Gente, K., Bertheussen, H., Bitoun, S., Bolek, E.C., and Burmester, G.R. (2024). 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. Ann. Rheum. Dis., online ahead of print.","DOI":"10.1136\/annrheumdis-2023-eular.4789"},{"key":"ref_3","first-page":"68","article-title":"Risk of Skin Cancer with Phototherapy in Moderate-to-Severe Psoriasis: An Updated Systematic Review","volume":"15","author":"Thatiparthi","year":"2022","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2024171","DOI":"10.5826\/dpc.1403a171","article-title":"Psoriasis with Leg Involvement as a New Difficult-to-Treat Area","volume":"14","author":"Bardazzi","year":"2024","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40259-022-00558-2","article-title":"Lower Limbs Are the Most Difficult-to-Treat Body Region in Psoriasis","volume":"36","author":"Duarte","year":"2022","journal-title":"BioDrugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2133.1994.tb04980.x","article-title":"Erythemal and Therapeutic Response of Psoriasis to PUVA Using High-Dose UVA","volume":"131","author":"Speight","year":"1994","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/07853890.2021.2022187","article-title":"Assessment of Efficacy and Safety of UV-Based Therapy for Psoriasis: A Network Meta-Analysis","volume":"54","author":"Li","year":"2022","journal-title":"Ann. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/1346-8138.70289","article-title":"Refractory Psoriatic Lesions in Japanese Patients with Biologics","volume":"53","author":"Ando","year":"2026","journal-title":"J. Dermatol."},{"key":"ref_9","first-page":"152","article-title":"Atypical Koebner response: Psoriasis remission following endovenous laser ablation for venous insufficiency: A Novel Case Report and Literature review","volume":"13","author":"Arslan","year":"2025","journal-title":"EMJ Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/jrms.jrms_364_25","article-title":"Linear psoriasis and Koebner phenomenon: A review","volume":"31","author":"Zheng","year":"2026","journal-title":"J. Res. Med. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Emmanuel, T., Ben Abdallah, H., Nielsen, M.M., Ignatov, B., Baez, E., Andersen, A.S., Waaben, L., Boye, M., Kaaber, I., and Boonen, D.S. (2026). Spatial Transcriptomic Profiling Reveals Body Site-Specific Inflammatory Differences in Psoriasis Lesions. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1706701"},{"key":"ref_12","first-page":"e2024058","article-title":"Can Biologic Agents Improve Treatment Success in Obese Patients with Psoriasis Vulgaris: A Retrospective Review of 320 Patients with Psoriasis Vulgaris","volume":"14","year":"2024","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jamadermatol.2025.0288","article-title":"Association of Obesity and Innate Immune Markers with Resistance to Biologic Therapy in Psoriasis","volume":"161","author":"Kim","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s13555-026-01664-7","article-title":"Management of Obesity in Psoriasis Consultations","volume":"16","author":"Nicolau","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wu, C.-L., Chang, Y.-C., Yao, W.-T., and Chiang, T.I. (2024). Exploring the Effectiveness of Biological Therapy in Patients with Psoriasis: Body Image and Quality of Life. Medicina, 60.","DOI":"10.3390\/medicina60010160"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2287401","DOI":"10.1080\/09546634.2023.2287401","article-title":"Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: An analysis from the CorEvitas psoriasis registry","volume":"35","author":"Strober","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/ijd.17729","article-title":"Diagnostic Performance of GPT-4o and Gemini Flash 2.0 in Acne and Rosacea","volume":"64","author":"Boostani","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_18","first-page":"e1052","article-title":"Large Language Models in Evaluating Hidradenitis Suppurativa from Clinical Images: A Diagnostic Performance Study","volume":"39","author":"Boostani","year":"2026","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4525\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:17:00Z","timestamp":1781230620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15124525"],"URL":"https:\/\/doi.org\/10.3390\/jcm15124525","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}